TiumBio, a Korean biotech company focusing on cancer and rare diseases, said it would participate in the 2022 BIO International Convention (BIO USA) to discuss partnerships with multinational drugmakers and biotech firms.

BIO USA is the world’s largest biotech and pharmaceutical partnering event. This year, the conference takes place in San Diego, Cal., in the U.S. from June 13-16. The upcoming event will be the first in-person meeting since 2019.

TiumBio will participate in the BIO USA’s partnering program to introduce endometriosis treatment candidate TU2670 and investigational immunotherapy TU2218.

The Kosdaq-listed company plans to meet with over 30 multinational pharmaceutical and biotech companies to discuss partnerships and joint research.

TiumBio CEO Kim Hun-taek said the conference would be an opportunity to discuss collaborations for the company’s various pipelines. “Through in-depth discussions, we will try our best to achieve meaningful results,” he said.

TiumBio is conducting phase 1/2 trials of immunotherapy TU2218 in the U.S. and Korea.

To use TU2218 in combination with MSD’s pembrolizumab (Keytruda) and BeiGene’s tislelizumab in trials, TiumBio signed an agreement with each company to use them for free in trials.

A phase 2 study of endometriosis drug TU2670 is also ongoing in Europe.

In addition, in the second half of this year, TiumBio will begin a clinical trial of hemophilia treatment TU7710.